How does HMGN's PB Ratio compare to its peers?

Insufficient data to calculate HMGN's Price-To-Book Ratio vs. peers for valuation analysis.

How does HMGN's PB Ratio compare vs other companies in the US Medical Equipment Industry?

Insufficient data to calculate HMGN's Price-To-Book Ratio vs. industry for valuation analysis.

What is HMGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate HMGN's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of HMGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate HMGN's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

HMGN Stock Overview

A biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. More details

HMGN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($15)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Hemagen Diagnostics, Inc. Competitors

Minerva Surgical

OTCPK:UTRS

US$887.0

Motus GI Holdings

OTCPK:MOTS

US$719.0

Lucira Health

OTCPK:LHDX.Q

US$4.2k

ETAO International

OTCPK:ETAO.F

US$5.0

Price History & Performance

Summary of share price highs, lows and changes for Hemagen Diagnostics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	HMGN	US Medical Equipment	US Market
7D	0%	-1.5%	-2.4%
1Y	n/a	10.1%	23.3%

Return vs Industry: Insufficient data to determine how HMGN performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how HMGN performed against the US Market.

Price Volatility

Is HMGN's price volatile compared to industry and market?
HMGN volatility
HMGN Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: HMGN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HMGN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1985	n/a	William Hales	www.hemagen.com

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines.

Hemagen Diagnostics, Inc. Fundamentals Summary

How do Hemagen Diagnostics's earnings and revenue compare to its market cap?
HMGN fundamental statistics
Market cap	US$15.00
Earnings (TTM)	-US$907.31k
Revenue (TTM)	US$4.04m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is HMGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HMGN income statement (TTM)
Revenue	US$4.04m
Cost of Revenue	US$2.43m
Gross Profit	US$1.61m
Other Expenses	US$2.52m
Earnings	-US$907.31k

Last Reported Earnings

Sep 30, 2012

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did HMGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 10:37
End of Day Share Price	2024/12/09 00:00
Earnings	2012/09/30
Annual Earnings	2012/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hemagen Diagnostics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution